Forte Biosciences, Inc.

Introduktion

Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for David W Gryska. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.

Gennemsnitlig handelsrentabilitet

Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.

Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.

Opdateringsfrekvens: Dagligt

Se listen over de mest profitable insiderhandlere.

Virksomheder med rapporterede insider-stillinger

SEC-registreringen viser, at David W Gryska har rapporteret besiddelser eller handler i følgende virksomheder:

Sikkerhed Titel Senest indberettede beholdninger
US:MNMD / Mind Medicine (MindMed) Inc. Director 19.851
US:SGEN / Seagen Inc Director 0
US:FBRX / Forte Biosciences, Inc. Director 148.514
US:AERI / Aerie Pharmaceuticals Inc Director 0
Director 0
US:69329YAE4 / PDL BioPharma, Inc. Bond 2.875% Director 1.387
US:INCY / Incyte Corporation Executive Vice President, CFO 10.235
US:HPTX / Hyperion Therapeutics Inc Director 9.800
Sådan fortolkes diagrammerne

Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af David W Gryska. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.

I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.

Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.

Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.

Insiderkøb FBRX / Forte Biosciences, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i FBRX / Forte Biosciences, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

FBRX / Forte Biosciences, Inc. Insider Trades
Insidersalg FBRX / Forte Biosciences, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i FBRX / Forte Biosciences, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

FBRX / Forte Biosciences, Inc. Insider Trades
Insiderkøb MNMD / Mind Medicine (MindMed) Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i FBRX / Forte Biosciences, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
2024-12-05 MNMD GRYSKA DAVID W 2.500 7,1700 2.500 7,1700 17.925 260 10.1900 7.550 42,12
2024-08-23 MNMD GRYSKA DAVID W 3.500 5,9800 3.500 5,9800 20.930

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

MNMD / Mind Medicine (MindMed) Inc. Insider Trades
Insidersalg MNMD / Mind Medicine (MindMed) Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i FBRX / Forte Biosciences, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

MNMD / Mind Medicine (MindMed) Inc. Insider Trades
Insiderhandelshistorie

Denne tabel viser den komplette liste over insiderhandler foretaget af David W Gryska som oplyst til Securities Exchange Commission (SEC).

Fil dato Transdato Form Ticker Sikkerhed Kode 10b5-1 Aktier Resterende aktier Procent
Lave om
Del
Pris
Tran
Værdi
Tilbage
Værdi
2024-12-05 2024-12-05 4 MNMD Mind Medicine (MindMed) Inc.
Common Shares
P - Purchase 2.500 19.851 14,41 7,17 17.925 142.332
2024-08-26 2024-08-23 4 MNMD Mind Medicine (MindMed) Inc.
Common Shares
P - Purchase 3.500 17.351 25,27 5,98 20.930 103.759
2023-12-15 2023-12-14 4 SGEN Seagen Inc.
Common Stock
D - Sale to Issuer -49.003 0 -100,00 229,00 -11.221.687
2023-08-02 2023-07-31 4 FBRX Forte Biosciences, Inc.
Common Stock
A - Award 148.514 148.514 1,01 149.999 149.999
2023-06-23 2023-06-21 4 MNMD Mind Medicine (MindMed) Inc.
Common Shares
A - Award 13.851 13.851
2023-06-02 2023-05-31 4 SGEN Seagen Inc.
Common Stock
A - Award 2.044 51.047 4,17
2023-02-15 2023-02-13 4 SGEN Seagen Inc.
Common Stock
M - Exercise 8.750 49.003 21,74 36,70 321.125 1.798.410
2022-11-21 2022-11-21 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
D - Sale to Issuer -1.996 0 -100,00 15,25 -30.439
2022-11-21 2022-11-21 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
D - Sale to Issuer -11.495 0 -100,00 15,25 -175.299
2022-11-15 2022-11-11 4 SGEN Seagen Inc.
Common Stock
S - Sale -7.500 40.253 -15,71 129,10 -968.220 5.196.501
2022-06-13 2022-06-09 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
A - Award 6.245 11.495 118,95
2022-05-17 2022-05-13 4 SGEN Seagen Inc.
Non-Qualified Stock Option (right to buy)
A - Award 3.676 3.676
2022-05-17 2022-05-13 4 SGEN Seagen Inc.
Common Stock
A - Award 1.503 47.753 3,25
2022-04-21 2022-04-19 4 SGEN Seagen Inc.
Non-Qualified Stock Option (right to buy)
M - Exercise -690 0 -100,00
2022-04-21 2022-04-19 4 SGEN Seagen Inc.
Non-Qualified Stock Option (right to buy)
M - Exercise -1.516 690 -68,72
2022-04-21 2022-04-19 4 SGEN Seagen Inc.
Non-Qualified Stock Option (right to buy)
M - Exercise -1.794 2.206 -44,85
2022-04-21 2022-04-19 4 SGEN Seagen Inc.
Common Stock
S - Sale X -690 46.250 -1,47 145,08 -100.105 6.709.950
2022-04-21 2022-04-19 4 SGEN Seagen Inc.
Common Stock
M - Exercise 690 46.940 1,49 20,06 13.841 941.616
2022-04-21 2022-04-19 4 SGEN Seagen Inc.
Common Stock
S - Sale X -1.516 46.250 -3,17 144,17 -218.562 6.667.862
2022-04-21 2022-04-19 4 SGEN Seagen Inc.
Common Stock
M - Exercise 1.516 47.766 3,28 20,06 30.411 958.186
2022-04-21 2022-04-19 4 SGEN Seagen Inc.
Common Stock
S - Sale X -1.794 46.250 -3,73 143,32 -257.116 6.628.550
2022-04-21 2022-04-19 4 SGEN Seagen Inc.
Common Stock
M - Exercise 1.794 48.044 3,88 20,06 35.988 963.763
2022-02-09 2022-02-07 4 SGEN Seagen Inc.
Non-Qualified Stock Option (right to buy)
M - Exercise -2.371 4.000 -37,22
2022-02-09 2022-02-07 4 SGEN Seagen Inc.
Non-Qualified Stock Option (right to buy)
M - Exercise -1.029 6.371 -13,91
2022-02-09 2022-02-07 4 SGEN Seagen Inc.
Non-Qualified Stock Option (right to buy)
M - Exercise -1.100 7.400 -12,94
2022-02-09 2022-02-07 4 SGEN Seagen Inc.
Common Stock
S - Sale X -2.371 46.250 -4,88 139,42 -330.565 6.448.175
2022-02-09 2022-02-07 4 SGEN Seagen Inc.
Common Stock
M - Exercise 2.371 48.621 5,13 20,06 47.562 975.337
2022-02-09 2022-02-07 4 SGEN Seagen Inc.
Common Stock
S - Sale X -1.029 46.250 -2,18 138,66 -142.681 6.413.025
2022-02-09 2022-02-07 4 SGEN Seagen Inc.
Common Stock
M - Exercise 1.029 47.279 2,22 20,06 20.642 948.417
2022-02-09 2022-02-07 4 SGEN Seagen Inc.
Common Stock
S - Sale X -1.100 46.250 -2,32 137,45 -151.195 6.357.062
2022-02-09 2022-02-07 4 SGEN Seagen Inc.
Common Stock
M - Exercise 1.100 47.350 2,38 20,06 22.066 949.841
2022-02-01 2022-01-28 4 SGEN Seagen Inc.
Non-Qualified Stock Option (right to buy)
M - Exercise -214 8.500 -2,46
2022-02-01 2022-01-28 4 SGEN Seagen Inc.
Non-Qualified Stock Option (right to buy)
M - Exercise -883 8.714 -9,20
2022-02-01 2022-01-28 4 SGEN Seagen Inc.
Non-Qualified Stock Option (right to buy)
M - Exercise -2.553 9.597 -21,01
2022-02-01 2022-01-28 4 SGEN Seagen Inc.
Non-Qualified Stock Option (right to buy)
M - Exercise -850 12.150 -6,54
2022-02-01 2022-01-28 4 SGEN Seagen Inc.
Common Stock
S - Sale X -214 46.250 -0,46 124,23 -26.585 5.745.638
2022-02-01 2022-01-28 4 SGEN Seagen Inc.
Common Stock
M - Exercise 214 46.464 0,46 20,06 4.293 932.068
2022-02-01 2022-01-28 4 SGEN Seagen Inc.
Common Stock
S - Sale X -883 46.250 -1,87 123,39 -108.953 5.706.788
2022-02-01 2022-01-28 4 SGEN Seagen Inc.
Common Stock
M - Exercise 883 47.133 1,91 20,06 17.713 945.488
2022-02-01 2022-01-28 4 SGEN Seagen Inc.
Common Stock
S - Sale X -2.553 46.250 -5,23 122,43 -312.564 5.662.388
2022-02-01 2022-01-28 4 SGEN Seagen Inc.
Common Stock
M - Exercise 2.553 48.803 5,52 20,06 51.213 978.988
2022-02-01 2022-01-28 4 SGEN Seagen Inc.
Common Stock
S - Sale X -850 46.250 -1,80 121,69 -103.436 5.628.162
2022-02-01 2022-01-28 4 SGEN Seagen Inc.
Common Stock
M - Exercise 850 47.100 1,84 20,06 17.051 944.826
2022-01-19 2022-01-14 4 SGEN Seagen Inc.
Non-Qualified Stock Option (right to buy)
M - Exercise -4.500 13.000 -25,71
2022-01-19 2022-01-14 4 SGEN Seagen Inc.
Common Stock
S - Sale X -4.500 46.250 -8,87 135,24 -608.581 6.254.859
2022-01-19 2022-01-14 4 SGEN Seagen Inc.
Common Stock
M - Exercise 4.500 50.750 9,73 20,06 90.270 1.018.045
2021-06-21 2021-06-17 4 AERI AERIE PHARMACEUTICALS INC
Stock Option (right to buy)
A - Award 7.800 7.800
2021-06-21 2021-06-17 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
A - Award 1.750 5.250 50,00
2021-05-18 2021-05-14 4 SGEN Seagen Inc.
Non-Qualified Stock Option (right to buy)
A - Award 3.462 3.462
2021-05-18 2021-05-14 4 SGEN Seagen Inc.
Common Stock
A - Award 1.402 46.250 3,13
2021-05-07 2021-05-05 4 GWPH GW PHARMACEUTICALS PLC
Share Options
D - Sale to Issuer -22.464 0 -100,00
2021-05-07 2021-05-05 4 GWPH GW PHARMACEUTICALS PLC
Share Options
D - Sale to Issuer -35.208 0 -100,00
2021-02-24 2021-02-22 4 GWPH GW PHARMACEUTICALS PLC
Share Options
A - Award 22.464 22.464
2020-12-31 2020-12-30 4 PDLI PDL BIOPHARMA, INC.
Common stock
S - Sale -20.000 1.387 -93,51 2,74 -54.800 3.800
2020-12-17 2020-12-16 4 PDLI PDL BIOPHARMA, INC.
Common stock
S - Sale -75.000 21.387 -77,81 2,68 -201.000 57.317
2020-12-09 2020-12-05 4 PDLI PDL BIOPHARMA, INC.
Stock Option (right to buy)
M - Exercise -66.050 0 -100,00 1,64 -108.322
2020-12-09 2020-12-05 4 PDLI PDL BIOPHARMA, INC.
Common stock
M - Exercise 66.050 96.387 217,72 1,64 108.322 158.075
2020-12-04 2020-12-03 4 PDLI PDL BIOPHARMA, INC.
Common stock
S - Sale -75.000 30.337 -71,20 2,52 -189.000 76.449
2020-11-24 2020-11-23 4 PDLI PDL BIOPHARMA, INC.
Common stock
S - Sale -50.000 105.337 -32,19 2,43 -121.500 255.969
2020-11-23 2020-11-19 4 SGEN Seagen Inc.
Non-Qualified Stock Option (right to buy)
M - Exercise -7.871 0 -100,00
2020-11-23 2020-11-19 4 SGEN Seagen Inc.
Non-Qualified Stock Option (right to buy)
M - Exercise -7.129 7.871 -47,53
2020-11-23 2020-11-19 4 SGEN Seagen Inc.
Common Stock
S - Sale -7.871 44.848 -14,93 173,25 -1.363.651 7.769.916
2020-11-23 2020-11-19 4 SGEN Seagen Inc.
Common Stock
M - Exercise 7.871 52.719 17,55 19,02 149.706 1.002.715
2020-11-23 2020-11-19 4 SGEN Seagen Inc.
Common Stock
S - Sale -7.129 44.848 -13,72 174,20 -1.241.872 7.812.522
2020-11-23 2020-11-19 4 SGEN Seagen Inc.
Common Stock
M - Exercise 7.129 51.977 15,90 19,02 135.594 988.603
2020-11-20 2020-11-18 4 PDLI PDL BIOPHARMA, INC.
Stock Option (right to buy)
M - Exercise -60.000 66.050 -47,60 1,64 -98.400 108.322
2020-11-20 2020-11-18 4 PDLI PDL BIOPHARMA, INC.
Common stock
M - Exercise 60.000 155.337 62,93 1,64 98.400 254.753
2020-11-19 2020-11-18 4 PDLI PDL BIOPHARMA, INC.
Common stock
S - Sale -50.000 95.337 -34,40 2,39 -119.500 227.855
2020-11-19 2020-11-17 4 PDLI PDL BIOPHARMA, INC.
Common stock
S - Sale -100.000 145.337 -40,76 2,40 -240.000 348.809
2020-11-06 2020-11-05 4 SGEN Seagen Inc.
Common Stock
S - Sale -4.500 44.848 -9,12 180,60 -812.699 8.099.540
2020-09-16 3 GWPH GW PHARMACEUTICALS PLC
No securities are beneficially owned
0
2020-09-16 2020-09-14 4 GWPH GW PHARMACEUTICALS PLC
Share Options
A - Award 35.208 35.208
2020-08-24 2020-08-19 4 PDLI PDL BIOPHARMA, INC.
Stock Option (right to buy)
A - Award 118.671 118.671 3,63 430.776 430.776
2020-08-24 2020-08-19 4 PDLI PDL BIOPHARMA, INC.
Common stock
A - Award 25.826 245.337 11,77
2020-06-29 2020-06-11 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
A - Award 1.750 5.496 46,72
2020-05-19 2020-05-15 4 SGEN SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy)
A - Award 3.171 3.171
2020-05-19 2020-05-15 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
A - Award 1.335 49.348 2,78
2019-10-03 2019-10-01 4 SGEN SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy)
M - Exercise -2.500 15.000 -14,29
2019-10-03 2019-10-01 4 SGEN SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy)
M - Exercise -2.500 15.000 -14,29
2019-10-03 2019-10-01 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
S - Sale X -2.500 48.013 -4,95 84,85 -212.125 4.073.903
2019-10-03 2019-10-01 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
M - Exercise 2.500 50.513 5,21 12,76 31.900 644.546
2019-10-03 2019-10-01 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
S - Sale X -2.500 48.013 -4,95 85,33 -213.325 4.096.949
2019-10-03 2019-10-01 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
M - Exercise 2.500 50.513 5,21 19,02 47.550 960.757
2019-07-19 2019-07-17 4 SGEN SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy)
M - Exercise -5.000 2.500 -66,67
2019-07-19 2019-07-17 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
S - Sale X -5.000 48.013 -9,43 75,00 -375.000 3.600.975
2019-07-19 2019-07-17 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
M - Exercise 5.000 53.013 10,41 12,76 63.800 676.446
2019-06-24 2019-06-20 4 PDLI PDL BIOPHARMA, INC.
Stock Option (right to buy)
A - Award 126.050 126.050 3,00 378.150 378.150
2019-05-23 2019-05-23 4 AERI AERIE PHARMACEUTICALS INC
Stock Option (right to buy)
A - Award 7.800 7.800
2019-05-23 2019-05-23 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
A - Award 1.750 1.750
2019-05-22 2019-05-20 4 SGEN SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy)
A - Award 7.038 7.038
2019-05-22 2019-05-20 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
A - Award 2.963 48.013 6,58
2019-04-03 2019-04-01 4 SGEN SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy)
M - Exercise -5.000 7.500 -40,00
2019-04-03 2019-04-01 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
S - Sale X -206 45.050 -0,46 74,01 -15.246 3.334.150
2019-04-03 2019-04-01 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
S - Sale X -4.794 45.256 -9,58 73,38 -351.784 3.320.885
2019-04-03 2019-04-01 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
M - Exercise 5.000 50.050 11,10 12,76 63.800 638.638
2019-01-10 2019-01-08 4 SGEN SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy)
M - Exercise -5.000 12.500 -28,57
2019-01-10 2019-01-08 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
S - Sale X -5.000 45.050 -9,99 65,04 -325.200 2.930.052
2019-01-10 2019-01-08 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
M - Exercise 5.000 50.050 11,10 12,76 63.800 638.638
2018-09-12 2018-09-12 4 AERI AERIE PHARMACEUTICALS INC
Stock Option (right to buy)
A - Award 25.000 25.000
2018-09-12 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
3.992
2018-09-12 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
3.992
2018-09-12 3 AERI AERIE PHARMACEUTICALS INC
Common Stock
3.992
2018-07-18 2018-07-16 4 INCY INCYTE CORP
Common Stock
F - Taxes -455 10.235 -4,26 70,19 -31.936 718.395
2018-07-05 2018-07-05 4 INCY INCYTE CORP
Common Stock
F - Taxes -280 10.690 -2,55 68,28 -19.118 729.913
2018-07-05 2018-07-02 4 INCY INCYTE CORP
Employee Stock Option (right to buy)
A - Award 22.772 22.772
2018-06-12 2018-06-08 4 PDLI PDL BIOPHARMA, INC.
Common stock
A - Award 54.348 219.511 32,91 2,76 150.000 605.850
2018-05-22 2018-05-18 4 SGEN SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy)
A - Award 9.260 9.260
2018-05-22 2018-05-18 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
A - Award 3.700 45.050 8,95
2018-02-22 2018-02-21 4 INCY INCYTE CORP
Common Stock
S - Sale X -1.952 10.970 -15,11 85,56 -167.013 938.593
2018-02-22 2018-02-20 4 INCY INCYTE CORP
Common Stock
F - Taxes -1.070 12.922 -7,65 86,03 -92.052 1.111.680
2018-01-25 2018-01-23 4 INCY INCYTE CORP
Employee Stock Option (right to buy)
A - Award 12.128 12.128
2018-01-09 2018-01-05 4 INCY INCYTE CORP
Non-Qualified Stock Option (right to buy)
M - Exercise -6.760 11.735 -36,55
2018-01-09 2018-01-05 4 INCY INCYTE CORP
Common Stock
S - Sale -6.760 13.992 -32,58 98,87 -668.361 1.383.389
2018-01-09 2018-01-05 4 INCY INCYTE CORP
Common Stock
M - Exercise 6.760 20.752 48,31 83,83 566.691 1.739.640
2017-11-03 2017-11-02 4 INCY INCYTE CORP
Common Stock
S - Sale X -3.915 13.992 -21,86 105,63 -413.541 1.477.975
2017-11-03 2017-11-01 4 INCY INCYTE CORP
Common Stock
F - Taxes -3.913 17.907 -17,93 107,96 -422.447 1.933.240
2017-09-15 2017-09-13 4 INCY INCYTE CORP
Common Stock
F - Taxes -712 21.820 -3,16 123,15 -87.683 2.687.133
2017-07-07 2017-07-05 4 INCY INCYTE CORP
Incentive Stock Option (right to buy)
A - Award 779 779
2017-07-07 2017-07-05 4 INCY INCYTE CORP
Non-Qualified Stock Option (right to buy)
A - Award 11.349 11.349
2017-07-07 2017-07-05 4 INCY INCYTE CORP
Common Stock
A - Award 3.517 22.532 18,50
2017-07-05 2017-06-30 4 INCY INCYTE CORP
Non-Qualified Stock Option (right to buy)
M - Exercise -599 3.591 -14,30
2017-07-05 2017-06-30 4 INCY INCYTE CORP
Common Stock
S - Sale -599 19.015 -3,05 129,74 -77.714 2.467.006
2017-07-05 2017-06-30 4 INCY INCYTE CORP
Common Stock
M - Exercise 599 19.614 3,15 73,21 43.853 1.435.941
2017-06-14 2017-06-12 4 INCY INCYTE CORP
Non-Qualified Stock Option (right to buy)
M - Exercise -16.756 4.190 -80,00
2017-06-14 2017-06-12 4 INCY INCYTE CORP
Common Stock
S - Sale -16.756 19.015 -46,84 116,60 -1.953.750 2.217.149
2017-06-14 2017-06-12 4 INCY INCYTE CORP
Common Stock
M - Exercise 16.756 35.771 88,12 73,21 1.226.707 2.618.795
2017-06-12 2017-06-09 4 PDLI PDL BIOPHARMA, INC.
Common stock
A - Award 60.729 165.163 58,15 2,47 150.001 407.953
2017-05-23 2017-05-19 4 SGEN SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy)
A - Award 9.260 9.260
2017-05-23 2017-05-19 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
A - Award 3.700 41.350 9,83
2017-05-02 2017-04-28 4 INCY INCYTE CORP
Non-Qualified Stock Option (right to buy)
M - Exercise -1.389 9.725 -12,50
2017-05-02 2017-04-28 4 INCY INCYTE CORP
Common Stock
S - Sale -1.389 19.015 -6,81 124,26 -172.597 2.362.804
2017-05-02 2017-04-28 4 INCY INCYTE CORP
Common Stock
M - Exercise 1.389 20.404 7,30 67,06 93.146 1.368.292
2017-04-11 2017-04-10 4 INCY INCYTE CORP
Non-Qualified Stock Option (right to buy)
M - Exercise -39.789 11.114 -78,17
2017-04-11 2017-04-10 4 INCY INCYTE CORP
Incentive Stock Option (right to buy)
M - Exercise -1.739 2.734 -38,88
2017-04-11 2017-04-10 4 INCY INCYTE CORP
Common Stock
S - Sale -39.789 19.015 -67,66 138,00 -5.490.882 2.624.070
2017-04-11 2017-04-10 4 INCY INCYTE CORP
Common Stock
S - Sale -1.739 58.804 -2,87 138,00 -239.982 8.114.952
2017-04-11 2017-04-10 4 INCY INCYTE CORP
Common Stock
M - Exercise 39.789 60.543 191,72 67,06 2.668.250 4.060.014
2017-04-11 2017-04-10 4 INCY INCYTE CORP
Common Stock
M - Exercise 1.739 20.754 9,15 67,06 116.617 1.391.763
2017-01-19 2017-01-17 4 INCY INCYTE CORP
Non-Qualified Stock Option (right to buy)
A - Award 19.091 19.091
2016-09-08 2016-09-06 4 SGEN SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy)
M - Exercise -10.000 0 -100,00
2016-09-08 2016-09-06 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
M - Exercise 10.000 37.650 36,17 10,20 102.000 384.030
2016-07-19 2016-07-15 4 INCY INCYTE CORP
Incentive Stock Option (right to buy)
A - Award 596 596
2016-07-19 2016-07-15 4 INCY INCYTE CORP
Non-Qualified Stock Option (right to buy)
A - Award 18.495 18.495
2016-07-19 2016-07-15 4 INCY INCYTE CORP
Common Stock
A - Award 5.555 19.015 41,27
2016-06-03 2016-06-02 4 PDLI PDL BIOPHARMA, INC.
Common stock
A - Award 71.023 104.434 212,57 3,52 250.001 367.608
2016-05-24 2016-05-20 4 SGEN SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy)
A - Award 9.260 9.260
2016-05-24 2016-05-20 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
A - Award 3.700 27.650 15,45
2016-01-08 2016-01-07 4 INCY INCYTE CORP
Incentive Stock Option (right to buy)
A - Award 1.044 1.044
2016-01-08 2016-01-07 4 INCY INCYTE CORP
Non-Qualified Stock Option (right to buy)
A - Award 2.995 2.995
2016-01-08 2016-01-07 4 INCY INCYTE CORP
Incentive Stock Option (right to buy)
A - Award 1.108 1.108
2016-01-08 2016-01-07 4 INCY INCYTE CORP
Non-Qualified Stock Option (right to buy)
A - Award 17.676 17.676
2016-01-08 2016-01-07 4 INCY INCYTE CORP
Common Stock
A - Award 2.610 13.460 24,06
2015-11-05 2015-11-05 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
S - Sale -10.000 23.950 -29,46 43,57 -435.737 1.043.590
2015-05-29 2015-05-28 4 PDLI PDL BIOPHARMA, INC.
Common stock
A - Award 22.059 33.411 194,32 6,80 150.001 227.195
2015-05-19 2015-05-15 4 SGEN SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy)
A - Award 9.260 9.260
2015-05-19 2015-05-15 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
A - Award 3.700 33.950 12,23
2015-04-14 2015-04-10 4 AERI AERIE PHARMACEUTICALS INC
Stock Option (right to buy)
A - Award 10.000 10.000
2015-04-14 2015-04-10 4 AERI AERIE PHARMACEUTICALS INC
Common Stock
A - Award 1.700 1.700
2015-04-10 2015-04-08 4 SGEN SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy)
M - Exercise -5.000 0 -100,00
2015-04-10 2015-04-08 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
M - Exercise 5.000 30.250 19,80 8,38 41.900 253.495
2015-01-09 2015-01-08 4 INCY INCYTE CORP
Incentive Stock Option (right to buy)
A - Award 599 599
2015-01-09 2015-01-08 4 INCY INCYTE CORP
Non-Qualified Stock Option (right to buy)
A - Award 20.946 20.946
2015-01-09 2015-01-08 4 INCY INCYTE CORP
Common Stock
A - Award 3.022 10.850 38,61
2014-11-04 2014-10-31 4 INCY INCYTE CORP
Non-Qualified Stock Option (right to buy)
A - Award 50.903 50.903
2014-11-04 2014-10-31 4 INCY INCYTE CORP
Incentive Stock Option (right to buy)
A - Award 4.473 4.473
2014-11-04 2014-10-31 4 INCY INCYTE CORP
Common Stock
A - Award 7.828 7.828
2014-06-13 2014-06-11 4 AERI AERIE PHARMACEUTICALS INC
Option (right to buy)
A - Award 13.500 13.500
2014-05-30 2014-05-28 4 PDLI PDL BIOPHARMA, INC.
Common stock
A - Award 5.371 11.352 89,80 9,31 50.004 105.687
2014-05-20 2014-05-16 4 SGEN SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy)
A - Award 8.750 8.750 34,25 299.688 299.688
2014-05-20 2014-05-16 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
A - Award 3.500 25.250 16,09
2014-03-10 2014-03-06 4 PDLI PDL BIOPHARMA, INC.
Common stock
A - Award 5.981 5.981 8,36 50.001 50.001
2014-02-10 2013-07-16 5 SGEN SEATTLE GENETICS INC /WA
Common Stock
G - Gift -250 21.750 -1,14
2013-09-05 2013-09-03 4 SGEN SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy)
M - Exercise -10.000 0 -100,00
2013-09-05 2013-09-03 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
S - Sale -10.000 22.000 -31,25 42,48 -424.800 934.560
2013-09-05 2013-09-03 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
M - Exercise 10.000 32.000 45,45 10,08 100.800 322.560
2013-05-21 2013-05-17 4 SGEN SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy)
A - Award 8.750 8.750 36,70 321.125 321.125
2013-05-21 2013-05-17 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
A - Award 3.500 22.000 18,92
2013-05-01 2013-04-15 4 HPTX HYPERION THERAPEUTICS INC
Stock Option (right to buy)
A - Award 9.800 9.800
2013-02-27 2013-02-26 4 SGEN SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy)
M - Exercise -5.000 5.000 -50,00
2013-02-27 2013-02-26 4 SGEN SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy)
M - Exercise -5.000 5.000 -50,00
2013-02-27 2013-02-26 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
M - Exercise 5.000 18.500 37,04 8,38 41.900 155.030
2013-02-27 2013-02-26 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
M - Exercise 5.000 13.500 58,82 5,00 25.000 67.500
2013-02-27 2013-02-25 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
S - Sale -10.000 8.500 -54,05 27,17 -271.700 230.945
2013-01-29 2012-08-06 5 SGEN SEATTLE GENETICS INC /WA
Common Stock
G - Gift -500 11.000 -4,35
2012-08-14 2012-08-10 4 SGEN SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy)
M - Exercise -7.500 5.000 -60,00
2012-08-14 2012-08-10 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
M - Exercise 7.500 19.000 65,22 5,00 37.500 95.000
2012-06-06 2012-06-05 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
S - Sale -8.000 11.500 -41,03 19,75 -158.000 227.125
2012-05-22 2012-05-18 4 SGEN SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy)
A - Award 17.500 17.500 20,06 351.050 351.050
2006-02-15 2006-02-14 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
A - Award 400 5.000 8,70 4,90 1.960 24.500
2006-02-15 2006-02-14 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
A - Award 1.752 4.600 61,52 4,91 8.602 22.586
2006-02-15 2006-02-14 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
A - Award 2.848 2.848 4,92 14.012 14.012
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)